CoChat

The DOI matches its Crossref record; 30 of the 32 references it cites were found in a registry or an index.

Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults

Schenck, Carlos H., Mahowald, Mark W. · 1996 · The American Journal of Medicine

Abstract

Purpose To assess the efficacy, dose stability, safety, and abuse potential of long-term, nightly benzodiazepine treatment of chronic disorders of disrupted nocturnal sleep.Patients and methods During a 12-year period, one author evaluated and treated 170 adult referrals for > or = 6 months with nightly benzodiazepine therapy for longstanding, sleep-disruptive disorders: injurious sleepwalking and sleep terrors (69); rapid eye movement sleep behavior disorder (52); chronic, severe insomnia (25); and restless legs syndrome/periodic limb movement disorder (24).Results Complete/substantial control of the sleep disorders was achieved by 146 patients (86%); 8% had adverse effects requiring medication changes; 2% had relapses of alcohol or chemical abuse requiring hospitalization; another 2% at times misused their medications. A total of 136 patients received clonazepam nightly for a mean 3.5 (+/- 2.4) years, with no significant difference in inital versus final mean dose: 0.77 mg (+/- 0.46) versus 1.10 mg (+/- 0.96). Similar results were obtained with chronic alprazolam treatment and with other benzodiazepine treatments.Conclusion Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep resulted in sustained efficacy in most cases, with low risk of dosage tolerance, adverse effects, or abuse. Data from this study on the treatment of chronic, severe insomnia (a small subset of all insomnia) are not generalizable to the typical insomnia patient.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0002-9343(97)89493-4

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 30 references

Cited by

See all 291

Metadata

Authors
Schenck, C. H., & Mahowald, M. W.
Affiliations
University of Minnesota (US)
Corresponding author
Schenck, Carlos H.
Venue
The American Journal of Medicine
Publisher
Elsevier BV
Published
1996-03
Volume
100
Issue
3
Pages
333-337
ISSN
0002-9343 (ISSN-L)
OpenAlex
W2084759069
Cited by
291
References
32
Citations by year
2026: 3 · 2025: 5 · 2024: 7 · 2023: 7 · 2022: 18 · 2021: 8 · 2020: 9 · 2019: 9 · 2018: 16 · 2017: 16 · 2016: 11 · 2015: 8 · 2014: 9 · 2013: 15 · 2012: 13
FWCI
10.13
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The American Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
  • Health Sciences › Medicine › Clinical Neurology › Restless Legs Syndrome Research
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Sleep and Wakefulness Research
Keywords
benzodiazepines, sleepwalking, sleep terrors, REM sleep behavior disorder, chronic insomnia, restless legs syndrome, periodic limb movement disorder, clonazepam, alprazolam, dose stability, medication abuse, adverse effects, treatment efficacy
MeSH terms
Adult, Alprazolam, Chronic Disease, Clonazepam, Drug Administration Schedule, Female, Humans, Sleep Initiation and Maintenance Disorders, Male, Restless Legs Syndrome, Sleep Wake Disorders, Somnambulism, Anti-Anxiety Agents, Treatment Outcome, Polysomnography, Substance-Related Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults. https://app.cochat.ai/papers/10.1016/s0002-9343(97)89493-4
The paper
Schenck, C. H., & Mahowald, M. W. (1996). Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults. The American Journal of Medicine. https://doi.org/10.1016/s0002-9343(97)89493-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.